恶性间皮瘤在中国的发病及诊治现状分析  

Epidemiology and clinical diagnosis and treatment of malignant mesothelioma in China

作　　者：陈凯燕[1] 郭振英[2] 苏丹[3] 毛伟敏[3] 

机构地区：[1]浙江中医药大学第二临床医学院,杭州310000 [2]浙江省肿瘤医院病理科,杭州310022 [3]浙江省肿瘤医院肿瘤研究所

出　　处：《中华胸心血管外科杂志》2017年第7期443-446,共4页Chinese Journal of Thoracic and Cardiovascular Surgery

基　　金：国家自然科学基金（81472203）

摘　　要：恶性间皮瘤是一种相对少见，与石棉暴露相关的高度侵袭性肿瘤。中国间皮瘤发病率呈明显上升趋势，多发生于胸膜和腹膜，大部分患者确诊时已为晚期，中位生存期12个月，预后较差。准确诊断有赖于组织病理学结合免疫组化检查。目前恶性间皮瘤的治疗主要是肿瘤减灭术或切除术结合化放疗的综合治疗方式。研究恶性间皮瘤诊断与治疗的潜在分子靶点具有重要意义。本文就恶性间皮瘤在中国的发病情况及诊治现状作一综述，希望为间皮瘤的早期诊断与规范治疗提供理论依据，改善间皮瘤患者的预后。Malignant mesothelioma（MM） is a rare but highly invasive carcinoma associated with asbestos exposure. Its incidence is in rising trend and most eases occur in pleura and peritoneum. The majority of patients diagnosed at late stage with poor prognosis that the median overall survival is only 12 months. Accurate diagnosis depends on the histopathology combined with immunohistochemistry. At present, the treatment of MM is mainly based on the tumor reduction or resection surgery com- bined with chemotherapy and radiotherapy. The potential molecular target needs to be further investigated. In this paper, we summary the ineidence, diagnosis and treatment of MM, which will benefit the diagnosis and treatment of MM in China.

关 键 词：恶性间皮瘤 发病率 中国 诊治 免疫组化检查 治疗方式 早期诊断 侵袭性肿瘤 

分 类 号：R734[医药卫生—肿瘤]